Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug discovery using Predictive’s active machine learning […]
~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”), a company transforming care […]
Transaction Strengthens Balance Sheet and Enables Execution of Multi-Vertical Revenue Strategy VANCOUVER, BC, March 21, 2025 /PRNewswire/ – Damon Inc. (NASDAQ: DMN) (“Damon” or the “Company”), a designer and developer of electric motorcycles and other personal mobility […]
ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil discussing the company’s drug development pipeline, and upcoming milestones.
Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn., March 17, 2025—-Hyperfine, Inc. (NASDAQ: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered […]
Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 — Lifeward Ltd., (NASDAQ: LFWD) (“Lifeward” or the “Company”), a […]
Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas, March 13, 2025—ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: […]
Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans Unusual Machines (NYSE: UMAC) CEO Allan Evans discusses UMAC growth strategy in multi-billion dollar US drone market. While the drone market is booming, Evans sees the […]
HOUSTON, March 06, 2025 — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the […]
FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN, Conn., March 03, 2025 — BioXcel Therapeutics, […]
– The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg/kg cohorts, respectively – – FREEDOM-DM1 15 […]
ScanTech AI is leading the charge in combating contraband in correctional facilities with cutting-edge artificial intelligence merged with advanced CT scanning technology Atlanta, GA, Feb. 18, 2025 — ScanTech AI Systems Inc. (NASDAQ: STAI) (“ScanTech […]
GARDEN CITY, NY, Feb. 18, 2025 — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, […]
NASHVILLE, Tenn., Feb. 4, 2025 — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. […]
SRC recommended that the trial escalate to the next dose level of 22mg capsule No dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 — Pasithea […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
